Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma
Benjamin E. Ueberroth, Jeremy Jones, Tanios Bekaii‐Saab
Topics & Concepts
MedicineOncologyKRASInternal medicineMinimal residual diseaseAdenocarcinomaCirculating tumor DNAComplete responseDiseaseChemotherapyCancerColorectal cancerLeukemiaCancer Genomics and DiagnosticsPancreatic and Hepatic Oncology ResearchCancer Cells and Metastasis